CDSCO Flags 132 Drug Batches in Latest Quality Alert, Including Essential Blood Pressure and Antibiotic Medications

NEW DELHI — India’s national drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has issued a comprehensive state-level alert flagging 132 batches of drugs, cosmetics, and medical formulations as “Not of Standard Quality” (NSQ). The latest monthly surveillance roundup includes critical, widely prescribed medications such as the antihypertensive drug telmisartan and the broad-spectrum antibiotic azithromycin, raising fresh questions regarding domestic manufacturing consistency and quality assurance.

The quality notices, published following extensive post-market testing across state drug testing laboratories—including facilities in Tamil Nadu, Gujarat, Punjab, Telangana, and Kerala—cover a broad spectrum of pharmaceuticals ranging from oral tablets and pediatric suspensions to injectable solutions and topicals.

What the CDSCO Alert Reveals

The CDSCO routinely publishes monthly NSQ notices as part of India’s statutory post-market surveillance under the Drugs and Cosmetics Act. Government laboratory testing evaluates sampled drugs across several vital pharmacopoeial criteria, including:

• Dissolution: How effectively a solid dosage form (like a tablet) breaks down to release its active ingredient into the bloodstream.

• Assay & Content Uniformity: Verifying whether each pill contains the exact amount of active pharmaceutical ingredient (API) stated on the label.

• Identification & Description: Ensuring proper chemical composition, appearance, and physical integrity.

• Sterility, pH, and Bacterial Endotoxins: Crucial quality metrics for liquid suspensions and injectable medications.

Crucial Regulatory Distinction: A CDSCO quality alert does not signify a blanket nationwide ban on a brand or molecule. Regulatory authorities emphasize that an NSQ declaration applies strictly to the specific batch number tested. Other batches of the same medication manufactured by the same or different companies remain unaffected unless specifically flagged.

High-Volume Essential Drugs Under Scrutiny

Among the 132 failed samples, the presence of telmisartan and azithromycin has drawn significant clinical focus due to their high volume of daily use:

When an antihypertensive medication like telmisartan fails dissolution testing, the drug may not absorb properly in the gastrointestinal tract, leading to under-dosing and unmanaged high blood pressure. Conversely, if an antibiotic like azithromycin suffers from assay deficiencies or sub-potent active ingredients, patients face therapeutic failure and an increased risk of developing antimicrobial resistance.

Understanding the Public Health Context

Post-market drug surveillance is an essential pillar of public health. While pre-market approvals establish a drug’s initial safety profile, post-market random sampling catches vulnerabilities occurring later in the supply chain—such as inadequate manufacturing process controls, raw material impurities, improper packaging, or degradation during storage and transit under ambient heat and humidity.

Public health specialists view these alerts as evidence that monitoring systems are working, while simultaneously pointing out that recurring batch failures highlight ongoing challenges in manufacturing oversight.

“Regular batch testing and public reporting show that state and central surveillance mechanisms are actively policing the supply chain,” notes Dr. Arisudan Sharma, an independent public health analyst and pharmaceutical supply policy specialist not involved in the regulatory audit. “However, the goal must extend beyond identifying bad batches. Sustainable public safety requires addressing root causes—strengthening good manufacturing practices (GMP), upgrading plant-level quality control, and ensuring rapid, traceable batch recalls.”

Actionable Guidance for Patients and Healthcare Providers

Regulatory agencies and medical experts advise a measured, evidence-based response to monthly NSQ alerts:

For Patients

• Do not stop taking prescribed medication abruptly. Abruptly discontinuing chronic medications like blood pressure treatments can trigger severe rebound health risks, such as hypertensive crises.

• Check your packaging. Compare the Batch Number and Manufacturer Name on your medicine package against the official CDSCO NSQ list.

• Consult your pharmacist or physician. If your specific batch matches a flagged lot number, take the package to your pharmacy or doctor to receive a replacement batch from an uncompromised lot.

For Healthcare Providers and Pharmacists

• Verify inventory: Pharmacy managers should cross-check current stock against the CDSCO batch numbers and quarantine affected units immediately.

• Traceability: Maintain batch-level records during dispensing to ensure rapid patient identification if a recall notice is issued.

• Pharmacovigilance: Report any unexpected lack of therapeutic efficacy or adverse drug reactions to national pharmacovigilance channels.

Study Limitations and Regulatory Realities

While NSQ alerts serve as an essential warning system, public reports often lack granular laboratory details. Without full analytical certificates for every listed batch, clinicians cannot always determine whether a failure stemmed from a minor packaging label variance or a critical active ingredient deficiency.

Furthermore, public health experts emphasize the importance of clear, non-sensational risk communication. Distinguishing between localized batch failures and systemic drug safety issues prevents unnecessary panic while preserving public trust in necessary pharmaceutical treatments.

References

1. Medical Dialogues News Bureau. CDSCO State Drug Alert: 132 Drug Batches Including Telmisartan, Azithromycin Fail Quality Tests. Published July 24, 2026.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.